PMC:7200337 / 91544-91692 JSONTXT

{"project":"2_test","denotations":[{"id":"32505227-32303591-46575417","span":{"begin":69,"end":73},"obj":"32303591"},{"id":"T66898","span":{"begin":69,"end":73},"obj":"32303591"}],"text":"athway have been proposed as therapeutic candidates (Moore and June, 2020) (Figure 6C). The commercial anti-IL-6R antibodies tocilizumab (Actemra) a"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T289","span":{"begin":83,"end":85},"obj":"Chemical"},{"id":"T290","span":{"begin":108,"end":110},"obj":"Chemical"},{"id":"T292","span":{"begin":125,"end":136},"obj":"Chemical"}],"attributes":[{"id":"A289","pred":"chebi_id","subj":"T289","obj":"http://purl.obolibrary.org/obo/CHEBI_27594"},{"id":"A290","pred":"chebi_id","subj":"T290","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A291","pred":"chebi_id","subj":"T290","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A292","pred":"chebi_id","subj":"T292","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"athway have been proposed as therapeutic candidates (Moore and June, 2020) (Figure 6C). The commercial anti-IL-6R antibodies tocilizumab (Actemra) a"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T204","span":{"begin":108,"end":113},"obj":"http://purl.obolibrary.org/obo/GO_0004915"}],"text":"athway have been proposed as therapeutic candidates (Moore and June, 2020) (Figure 6C). The commercial anti-IL-6R antibodies tocilizumab (Actemra) a"}

{"project":"LitCovid-PubTator","denotations":[{"id":"3026","span":{"begin":108,"end":113},"obj":"Gene"},{"id":"3035","span":{"begin":125,"end":136},"obj":"Chemical"}],"attributes":[{"id":"A3026","pred":"tao:has_database_id","subj":"3026","obj":"Gene:3570"},{"id":"A3035","pred":"tao:has_database_id","subj":"3035","obj":"MESH:C502936"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"athway have been proposed as therapeutic candidates (Moore and June, 2020) (Figure 6C). The commercial anti-IL-6R antibodies tocilizumab (Actemra) a"}